Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 7% – Should You Sell?

Capricor Therapeutics Inc (NASDAQ:CAPR) shares traded down 7% on Wednesday . The company traded as low as $17.46 and last traded at $17.98. 1,433,298 shares changed hands during trading, an increase of 38% from the average session volume of 1,039,810 shares. The stock had previously closed at $19.33.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a report on Tuesday, September 24th. Maxim Group raised their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Cantor Fitzgerald reissued an “overweight” rating and set a $8.00 price objective on shares of Capricor Therapeutics in a report on Friday, September 20th. Finally, Oppenheimer reissued an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Capricor Therapeutics Trading Down 6.6 %

The company has a market capitalization of $577.22 million, a P/E ratio of -20.67 and a beta of 4.01. The stock’s 50-day moving average price is $6.63 and its 200-day moving average price is $5.84.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The firm had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. Sell-side analysts expect that Capricor Therapeutics Inc will post -1.14 earnings per share for the current fiscal year.

Insider Transactions at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The stock was acquired at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the acquisition, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.00% of the stock is currently owned by insiders.

Institutional Trading of Capricor Therapeutics

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets bought a new stake in Capricor Therapeutics in the first quarter worth approximately $40,000. Main Street Financial Solutions LLC grew its position in Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares in the last quarter. SG Americas Securities LLC bought a new stake in Capricor Therapeutics in the third quarter worth approximately $133,000. Rhumbline Advisers bought a new stake in Capricor Therapeutics in the second quarter worth approximately $147,000. Finally, Bank of New York Mellon Corp grew its position in Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after acquiring an additional 9,040 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.